30 likes | 36 Views
Epilepsy is a chronic brain disorder, making it one of the most prevalent neurological conditions worldwide. Get more insights into the Epilepsy Devices Market.
E N D
Epilepsy Devices Market: Tech Trends 2022-2028 AccordingtotheWHO,epilepsyisachronicbraindisorderthataffects50millionindividuals,makingitoneofthemostprevalentneurologicalconditionsworldwide.Itisestimatedthatwithaccesstoearlydetectionandappropriatecare,70%ofthepopulationdiagnosedwithepilepsymayliveseizure-free.Accordingtoourestimates,theglobal epilepsy devices marketwasvaluedat$669.73millionin2021andisexpectedtoreach$1157.58millionby2028,growingataCAGRof8.16%duringtheforecastperiod2022-2028. GovernmentinstitutionsworldwidearefocusedonstartinginitiativestocreateinnovativeepilepsydeviceswithAIandmachinelearningintegration.Additionally,organizationsthatsupportresearchneedtoencouragehigh-qualitycomparativeefficacytrialsandsufficientdatatoguidetherapeuticpracticeinepilepsy.Asaresultofthesetechnologicallyadvancedequipmentandincreasingdrugtrials,themarketforepilepsydevicesisanticipatedtogrowthroughouttheforecastperiod. • EpilepsyDevices-KeyDetectionMethodologies • Currently,severalwearabletechnologiescandetectseizures,collectdata,andalertcaregivers.Althoughwithtechnologicaladvancements,theabilitytodetectseizure-relatedalterationsincreases.Toptrendsbackingthistechboominclude: • Wearabledevicesareestimatedtobethefastest-growingdevicetypeduringtheforecastperiod.Monitoringepilepticpatientsiscrucial,as20%ofepilepticsonlyhaveseizureswhileasleep,40%onlyhaveseizureswhileawake,and35%haveseizuresbothwhentheyareawakeandasleep.Withtechnologicallyadvancednon-invasivewearablesensors,measuringaccelerometry,photoplethysmography(PPG),electrodermalactivity(EDA),
electromyography(EMG),andothersignalsoutsideoftheconventionalclinicalenvironmenthavebecomeeffective.electromyography(EMG),andothersignalsoutsideoftheconventionalclinicalenvironmenthavebecomeeffective. • VagusNerveStimulation(VNS)hasemergedasthefastest-growingapplicationcategory.VNSTherapyhasbeenapprovedbytheU.S.FoodandDrugAdministration(FDA)asanadd-ontherapyforage4yearsandabovetotreatdrug-resistantepilepsyorrefractoryepilepsy.VNShasbeenreportedlybeneficialinmanypatients,includingtheoneswithposttraumaticepilepsy(PTE).PTEisacommonconsequenceoftraumaticbraininjuryandaccountsforabout20%ofsymptomaticepilepsycases. • Asperestimates,Electroencephalographyleadthedetectionandpredictiondevicestypesegmentin2021andisexpectedtomaintainitsstrongholdduringtheforecastperiod.Thereis growing interest in wearable or mobile EEG solutions that allow long‐term EEG monitoring inan easy‐to‐use format. DespitetheavailabilityofthesenewEEGsolutions,theiradoptionisstilllimitedinclinicalpractice,mainlybecauseoftheunfamiliarityofhealthcareandbiomedicalresearchsectorswiththetechnologyanditsapplication. • StrategicInitiativesandGovernmentApprovals • Differentend-users,suchashomecaresettings,hospitals,andclinics,areutilizingepilepsydevices.Themanufacturersofepilepsymonitoringdevicesarelikelytogainprominentbusinessopportunitiesfromthehospital&clinicssegmentowingtotheriseintheuseofEEGmonitoringandemergencymedicalservices. • Thegovernmentauthoritiesofseveraldevelopingnations,includingIndiaandChina,arefocusingondevelopingsturdyhealthcareinfrastructure.Asaresult,operatingplayersareexpectedtogainsizablegrowthprospectsintheregionduringtheforecastperiod.Owingtothis,theAsia PacificepilepsydevicesmarketisanticipatedtowitnessthefastestgrowthwithaCAGRof8.38% Kommentar[A1]:HyperlinkthisFramewithrevenuestatement throughouttheforecastperiod. • Inaddition,companiesarealsofocusingonlaunchingnoveldevicesforchildren.Moreover,companiesarealsousingorganicandinorganicstrategies,includingmergersandacquisitions,tostayaheadofthecompetition.Someoftheseinclude: • InSeptember2022,BostonScientificCorporation’scurrent-generation WATCHMAN FLX™ LeftAtrialAppendageClosure(LAAC)DevicereceivedU.S.FoodandDrugAdministration(FDA)approvaltoexpandtheinstructionsforuselabeling.ThecompanyalsoreceivedFDA510(k)clearancefortheEMBOLDFiberedDetachableCoil,whichreducesthebloodflowrateintheperipheralvasculature. • InJuly2022,MedtronicPLCreceivedFDA510(k)clearanceforitsUNiDSpineAnalyzerv4.0planningplatformtoleveragemachinelearning. • InNovember2021,NeuroPace,Inc.receivedanInvestigationalDeviceExemption(IDE)fromtheFDAtostudythecompany’sRNSSystemtotreatprimarygeneralizedepilepsyinpatientsaged12andabove. • WayForward • Withtechnologicaladvancements,epilepsydetectiondeviceswithexceptionallylowfalsealarmrateshaverecentlybeendeveloped.Theyarebasedoncomputationallyintensivealgorithmsandemployedinimplantedsystemsforpre-surgicalmonitoring.Recentresearchhasproducedencouragingfindingsforprobabilisticseizureriskprojectionsusinglong-termwearabletechnology
andelectronicseizurediaries.Thesymptoms,mood,andcognitivefunctionofanindividualmayalsohavepredictivesignificance.Therefore,technologicaladvancesinnon-invasivewearablesensorsareanticipatedtocreategrowthopportunitiesfortheepilepsydevicesmarket.andelectronicseizurediaries.Thesymptoms,mood,andcognitivefunctionofanindividualmayalsohavepredictivesignificance.Therefore,technologicaladvancesinnon-invasivewearablesensorsareanticipatedtocreategrowthopportunitiesfortheepilepsydevicesmarket. FAQ: Q1)Whatarethekeyend-usersoftheepilepsydevicesmarket? Thekeyend-usersintheepilepsydevicesmarketincludehospitals&clinics,neurologycenters,homecaresettings,andotherend-users. Q2)Whichregionleadstheglobalepilepsydevicesmarket?NorthAmericaleadstheglobalepilepsydevicesmarket.